1. Home
  2. Browse
  3. HRA007955
HRA007955
   HRA007955.xlsx
Title:
Reversing Immunosenescence with Senolytics to Enhance Tumor Immunotherapy
Release date:
2025-04-24
Description:
Recent advancements in cancer immunotherapy have significantly improved patient outcomes, yet responses remain moderate. In a phase II clinical trial OOC 001, NCT04718415 involving 51 cancer patients, we conducted singlecell RNA and TCR or BCR sequencing on tumor and blood samples. Our findings associate poor immunotherapy response with reduced levels of CCR7+ CD4 Naive T cells and CD27 Memory B cells, as well as higher expression of immunosenescence-related genes in T and B cell subsets of non-responders. Importantly, studies using syngeneic mouse models and an Ercc1 aging mouse model, along with ongoing trials COIS 01, NCT05724329, validate that senolytics enhance the therapeutic efficacy of immunotherapy in multiple solid tumors by mitigating tumor immunosenescence. These results underscore the critical role of immunosenescence and its senescent features in the tumor microenvironment on immunotherapy outcomes, suggesting that modulation could enhance cancer immunotherapy efficacy.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA027702
Study type:
Disease Study
Disease name:
head and neck squamous cell carcinoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC004348
DAC name:
Fan Lab
Contact person:
Fan Song
Email:
fansong2@mail.sysu.edu.cn
Description:
The Commitee is responsile for reviewing and authorizing requests for acces to controled data in accordance with consent andcr naional Research ethics provisions.
Individuals & samples
Files
Request Data
Submitter:   Fan Song / fansong2@mail.sysu.edu.cn
Organization:   Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Submission date:   2024-06-29
Requests:   7